why choose us

First received: June 07, 2023

Clinical Trial: Do Alemtuzumab Levels Predict T Cell Chimerism After MSD SCT for SCD?

Study Status: Completed

Recruit Status: RECRUITING

Condition: Sickle Cell Disease

Study Type: OBSERVATIONAL


Official Title: Do Serum Alemtuzumab Concentrations Predict Donor T Cell Chimerism After Non-Myeloablative Matched Sibling Donor Stem Cell Transplantation in Sickle Cell Disease Patients

Brief Summary: Rationale: Non-myeloablative allogeneic stem cell transplantation (SCT) has become a feasible curative treatment option for sickle cell disease (SCD) patients with an available matched sibling donor.Chemotherapy free conditioning with alemtuzumab and 3 Gy total body irradiation (TBI) is increasingly being used as preferred conditioning scheme for these patients.This regimen typically results in mixed donor chimerism and has only few toxic effects.However, the risk of graft failure (rejection) is still significant,…

Read more